

Applicants : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
Page 4

consists entirely of L-amino acids.

125. (New) The method of claim 123, wherein the purified polypeptide consists entirely of D-amino acids.

126. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 1.

127. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 2.

128. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 3.

129. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 4.

130. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 5.

131. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 6.

132. (New) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 7.

133. (New) A method of treating or preventing an autoimmune disease in a mammal comprising administering to the mammal a pharmaceutical composition consisting essentially of a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, and a pharmaceutically

Applicants : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
Page 5

acceptable carrier.

134. (New) The method of claim 123 or 133 wherein said autoimmune disease is a B cell mediated autoimmune disease, a T cell mediated autoimmune disease, a demyelinating disease, an inflammatory disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

135. (New) The method of Claim 134, wherein said autoimmune disease is a B cell mediated autoimmune disease.

136. (New) The method of Claim 134, wherein said autoimmune disease is a T cell mediated autoimmune disease.

137. (New) The method of Claim 134, wherein said autoimmune disease is a demyelinating disease.

138. (New) The method of Claim 134, wherein said autoimmune disease is multiple sclerosis.

139. (New) The method of Claim 134, wherein said autoimmune disease is an inflammatory disease.

140. (New) The method of Claim 134, wherein said autoimmune disease is rheumatoid arthritis.

141. (New) The method of Claim 134, wherein said autoimmune disease

Applicants : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
Page 6

is osteoarthritis.

142. (New) A method of treating or preventing graft versus host disease (GVHD), host versus graft disease (HVGD) or delayed-type hypersensitivity (DTH) in a mammal comprising administering to the mammal a purified polypeptide having the amino acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.

143. (New) A method of determining molecular weight of glatiramer acetate comprising calibrating a chromatographic apparatus that is used for molecular weight determination with a purified polypeptide having the amino acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 and determining the molecular weight of the glatiramer acetate using the calibrated chromatographic apparatus that is used for molecular weight determination.